111614
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
曲妥珠单抗长期用于治疗 HER2 阳性转移性乳腺癌期间出现的迟发性心脏功能障碍
Authors Chen X, Lan X, Xiao L, Song L, Huang J , Xie X, Chen L, Bai X, Du C
Received 25 July 2025
Accepted for publication 12 November 2025
Published 25 November 2025 Volume 2025:17 Pages 1101—1110
DOI https://doi.org/10.2147/BCTT.S553442
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Robert Clarke
Xuelian Chen,* Xiaofeng Lan,* Li Xiao, Lin Song, Jiayi Huang, Xiaofeng Xie, Liping Chen, Xue Bai, Caiwen Du
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Caiwen Du, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People’s Republic of China, Tel +86-075566618227, Email dusumc@aliyun.com
Background: Cardiotoxicity is the most concerning side effect of trastuzumab in HER2-positive metastatic breast cancer. However, data on the delayed cardiac safety of long-term trastuzumab are rare.
Patients and Methods: A retrospective review of patients with HER2-positive breast cancer receiving trastuzumab for more than 24 months in a metastatic setting was conducted. Patients with medical records of regular assessment of the left ventricular ejection fraction (LVEF) and serum brain natriuretic peptide (BNP) level were included. The incidence of cardiac events and possible predictive factors were analyzed.
Results: A total of 75 patients were eligible for the current cardiac safety analyses. The median trastuzumab exposure was 50 (range: 29– 114) cycles. By the cut-off time, the median follow-up time for cardiotoxicity was 34.0 (range: 26.0– 41.9) months. The median timing of occurrence of a decrease in LVEF was 8.3 months after follow-up, mostly occurring within the third year from the initiation of trastuzumab. The cumulative incidence of LVEF decline was 10.7% (n=8) after 24-month trastuzumab. Patients with a history of anthracycline administration had a higher incidence of LVEF reduction (13.0% vs 3.6%, p=0.006). Five patients recovered soon after the cessation of trastuzumab. One patient died from congestive heart failure. BNP elevations were noted in 42.7% of patients, but elevated BNP levels could not identify patients with cardiotoxicity.
Conclusion: Of the patients who had received long-term trastuzumab for more than 24 months, delayed cardiotoxicity was observed in only a small subset, and was reversible in most of them. Elevation of serum BNP could not predict cardiotoxicity. Less frequent LVEF monitoring could be considered during long-term use of trastuzumab.
Keywords: cardiotoxicity, long-term, trastuzumab, HER2-positive
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Caiwen Du, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, People’s Republic of China, Tel +86-075566618227, Email dusumc@aliyun.com
Background: Cardiotoxicity is the most concerning side effect of trastuzumab in HER2-positive metastatic breast cancer. However, data on the delayed cardiac safety of long-term trastuzumab are rare.
Patients and Methods: A retrospective review of patients with HER2-positive breast cancer receiving trastuzumab for more than 24 months in a metastatic setting was conducted. Patients with medical records of regular assessment of the left ventricular ejection fraction (LVEF) and serum brain natriuretic peptide (BNP) level were included. The incidence of cardiac events and possible predictive factors were analyzed.
Results: A total of 75 patients were eligible for the current cardiac safety analyses. The median trastuzumab exposure was 50 (range: 29– 114) cycles. By the cut-off time, the median follow-up time for cardiotoxicity was 34.0 (range: 26.0– 41.9) months. The median timing of occurrence of a decrease in LVEF was 8.3 months after follow-up, mostly occurring within the third year from the initiation of trastuzumab. The cumulative incidence of LVEF decline was 10.7% (n=8) after 24-month trastuzumab. Patients with a history of anthracycline administration had a higher incidence of LVEF reduction (13.0% vs 3.6%, p=0.006). Five patients recovered soon after the cessation of trastuzumab. One patient died from congestive heart failure. BNP elevations were noted in 42.7% of patients, but elevated BNP levels could not identify patients with cardiotoxicity.
Conclusion: Of the patients who had received long-term trastuzumab for more than 24 months, delayed cardiotoxicity was observed in only a small subset, and was reversible in most of them. Elevation of serum BNP could not predict cardiotoxicity. Less frequent LVEF monitoring could be considered during long-term use of trastuzumab.
Keywords: cardiotoxicity, long-term, trastuzumab, HER2-positive